 Joseph Schacht
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 24 | 2024 | 713 | 5.870 |
Why?
| | Naltrexone | 7 | 2021 | 83 | 3.040 |
Why?
| | Catechol O-Methyltransferase | 4 | 2022 | 17 | 2.200 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 5 | 2021 | 41 | 2.070 |
Why?
| | Cues | 16 | 2024 | 300 | 2.050 |
Why?
| | Receptors, Opioid, mu | 5 | 2021 | 52 | 1.610 |
Why?
| | Alcohol Drinking | 15 | 2024 | 651 | 1.500 |
Why?
| | Marijuana Abuse | 8 | 2019 | 212 | 1.490 |
Why?
| | Narcotic Antagonists | 4 | 2021 | 136 | 1.440 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2020 | 1879 | 1.120 |
Why?
| | gamma-Aminobutyric Acid | 4 | 2019 | 144 | 1.050 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2019 | 159 | 1.050 |
Why?
| | Brain | 16 | 2024 | 2371 | 1.030 |
Why?
| | Magnetic Resonance Imaging | 18 | 2024 | 3039 | 0.870 |
Why?
| | Craving | 4 | 2024 | 32 | 0.860 |
Why?
| | Pharmacogenomic Variants | 3 | 2017 | 33 | 0.820 |
Why?
| | Flumazenil | 2 | 2013 | 6 | 0.810 |
Why?
| | Cyclohexanecarboxylic Acids | 2 | 2013 | 22 | 0.790 |
Why?
| | Amines | 2 | 2013 | 34 | 0.790 |
Why?
| | Reward | 5 | 2020 | 211 | 0.770 |
Why?
| | Aripiprazole | 2 | 2017 | 17 | 0.740 |
Why?
| | Alcohol Deterrents | 2 | 2018 | 17 | 0.740 |
Why?
| | Dopamine Agonists | 2 | 2017 | 32 | 0.720 |
Why?
| | Substance-Related Disorders | 3 | 2024 | 947 | 0.670 |
Why?
| | Receptor, Cannabinoid, CB1 | 4 | 2012 | 28 | 0.640 |
Why?
| | Cocaine | 1 | 2021 | 153 | 0.630 |
Why?
| | Functional Neuroimaging | 4 | 2024 | 70 | 0.630 |
Why?
| | Dopamine | 2 | 2022 | 236 | 0.610 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 610 | 0.580 |
Why?
| | Cognition | 3 | 2018 | 988 | 0.570 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 520 | 0.570 |
Why?
| | Dopamine Agents | 1 | 2016 | 14 | 0.530 |
Why?
| | Glutamic Acid | 5 | 2019 | 211 | 0.520 |
Why?
| | Prefrontal Cortex | 2 | 2016 | 262 | 0.520 |
Why?
| | Ethanol | 6 | 2024 | 538 | 0.510 |
Why?
| | Nicotine | 1 | 2018 | 265 | 0.500 |
Why?
| | Brain Mapping | 4 | 2017 | 524 | 0.500 |
Why?
| | Motivation | 6 | 2020 | 494 | 0.480 |
Why?
| | Amidohydrolases | 3 | 2009 | 28 | 0.480 |
Why?
| | Benzazepines | 1 | 2014 | 37 | 0.450 |
Why?
| | Smoking | 2 | 2018 | 1380 | 0.450 |
Why?
| | Quinoxalines | 1 | 2014 | 60 | 0.440 |
Why?
| | Adult | 26 | 2024 | 30528 | 0.420 |
Why?
| | Nicotinic Agonists | 1 | 2014 | 100 | 0.420 |
Why?
| | Cannabis | 1 | 2018 | 384 | 0.390 |
Why?
| | Young Adult | 17 | 2020 | 10455 | 0.390 |
Why?
| | Humans | 41 | 2024 | 114623 | 0.390 |
Why?
| | Marijuana Smoking | 2 | 2019 | 224 | 0.370 |
Why?
| | Male | 28 | 2021 | 55554 | 0.370 |
Why?
| | Alcohol-Related Disorders | 1 | 2012 | 113 | 0.370 |
Why?
| | Amygdala | 1 | 2012 | 170 | 0.360 |
Why?
| | Genotype | 6 | 2020 | 1760 | 0.360 |
Why?
| | Female | 28 | 2024 | 59466 | 0.360 |
Why?
| | Genetic Variation | 2 | 2012 | 870 | 0.350 |
Why?
| | Catechol O-Methyltransferase Inhibitors | 2 | 2022 | 3 | 0.340 |
Why?
| | Corpus Striatum | 1 | 2011 | 126 | 0.340 |
Why?
| | Treatment Outcome | 7 | 2021 | 9084 | 0.330 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2011 | 222 | 0.320 |
Why?
| | Glutamine | 2 | 2019 | 91 | 0.310 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2084 | 0.310 |
Why?
| | Gyrus Cinguli | 4 | 2019 | 70 | 0.310 |
Why?
| | Hippocampus | 1 | 2012 | 693 | 0.300 |
Why?
| | Heterozygote | 2 | 2018 | 251 | 0.270 |
Why?
| | Receptors, Dopamine D2 | 2 | 2017 | 86 | 0.270 |
Why?
| | Middle Aged | 10 | 2021 | 26719 | 0.260 |
Why?
| | Antipsychotic Agents | 2 | 2017 | 184 | 0.240 |
Why?
| | Neuroimaging | 2 | 2024 | 249 | 0.230 |
Why?
| | Pharmacogenetics | 2 | 2016 | 149 | 0.220 |
Why?
| | Nerve Net | 2 | 2018 | 226 | 0.220 |
Why?
| | Behavior, Addictive | 3 | 2019 | 81 | 0.210 |
Why?
| | Biomarkers | 3 | 2024 | 3408 | 0.200 |
Why?
| | Adolescent | 12 | 2024 | 17831 | 0.200 |
Why?
| | Cartilage Oligomeric Matrix Protein | 1 | 2021 | 2 | 0.190 |
Why?
| | Gene Frequency | 2 | 2016 | 477 | 0.190 |
Why?
| | Checklist | 1 | 2022 | 83 | 0.190 |
Why?
| | Ventral Striatum | 1 | 2020 | 8 | 0.180 |
Why?
| | Anesthesia, General | 1 | 2021 | 44 | 0.180 |
Why?
| | Appointments and Schedules | 1 | 2021 | 72 | 0.180 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 151 | 0.170 |
Why?
| | Aspartic Acid | 2 | 2019 | 77 | 0.170 |
Why?
| | Alcohol Abstinence | 1 | 2019 | 10 | 0.170 |
Why?
| | Drug Therapy, Combination | 2 | 2013 | 951 | 0.160 |
Why?
| | Homozygote | 2 | 2016 | 187 | 0.160 |
Why?
| | Binge Drinking | 1 | 2019 | 32 | 0.160 |
Why?
| | Avoidance Learning | 1 | 2019 | 63 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2019 | 58 | 0.160 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4411 | 0.150 |
Why?
| | Glycine | 1 | 2019 | 152 | 0.150 |
Why?
| | Frontal Lobe | 1 | 2019 | 141 | 0.150 |
Why?
| | Transferrin | 1 | 2018 | 39 | 0.150 |
Why?
| | Receptors, Dopamine D4 | 1 | 2017 | 24 | 0.150 |
Why?
| | Minisatellite Repeats | 1 | 2017 | 38 | 0.150 |
Why?
| | Case-Control Studies | 3 | 2019 | 3003 | 0.150 |
Why?
| | Sialoglycoproteins | 1 | 2018 | 159 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2537 | 0.150 |
Why?
| | Self Administration | 1 | 2017 | 122 | 0.140 |
Why?
| | DNA Methylation | 1 | 2021 | 495 | 0.140 |
Why?
| | Central Nervous System Depressants | 1 | 2017 | 81 | 0.140 |
Why?
| | Double-Blind Method | 2 | 2019 | 1660 | 0.140 |
Why?
| | Recurrence | 3 | 2020 | 935 | 0.140 |
Why?
| | Drug Interactions | 1 | 2018 | 338 | 0.140 |
Why?
| | Self-Control | 1 | 2017 | 48 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1796 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2017 | 258 | 0.130 |
Why?
| | Impulsive Behavior | 1 | 2017 | 113 | 0.130 |
Why?
| | Receptors, Dopamine D1 | 1 | 2016 | 25 | 0.130 |
Why?
| | Hemodynamics | 1 | 2021 | 1012 | 0.130 |
Why?
| | Stress, Psychological | 1 | 2024 | 944 | 0.130 |
Why?
| | Visual Perception | 1 | 2017 | 139 | 0.130 |
Why?
| | Receptors, GABA-A | 1 | 2016 | 82 | 0.130 |
Why?
| | Attention | 1 | 2018 | 393 | 0.120 |
Why?
| | Cocaine-Related Disorders | 1 | 2015 | 107 | 0.120 |
Why?
| | Adolescent Behavior | 1 | 2019 | 489 | 0.110 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 927 | 0.110 |
Why?
| | Varenicline | 1 | 2014 | 22 | 0.110 |
Why?
| | Pilot Projects | 2 | 2019 | 1372 | 0.110 |
Why?
| | Sex Factors | 1 | 2018 | 1715 | 0.110 |
Why?
| | GABA Modulators | 1 | 2013 | 7 | 0.110 |
Why?
| | Tobacco Use Disorder | 1 | 2015 | 234 | 0.110 |
Why?
| | Tandem Repeat Sequences | 1 | 2012 | 17 | 0.100 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2013 | 87 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 336 | 0.100 |
Why?
| | Patient Selection | 1 | 2016 | 641 | 0.100 |
Why?
| | Surveys and Questionnaires | 3 | 2016 | 4620 | 0.100 |
Why?
| | Prognosis | 2 | 2017 | 3328 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2012 | 44 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2387 | 0.100 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 76 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2013 | 222 | 0.100 |
Why?
| | Functional Laterality | 1 | 2012 | 198 | 0.100 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 493 | 0.090 |
Why?
| | Positron-Emission Tomography | 1 | 2012 | 259 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 321 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2012 | 339 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2094 | 0.090 |
Why?
| | Prospective Studies | 2 | 2018 | 6217 | 0.090 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 20 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 413 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 768 | 0.080 |
Why?
| | Phenotype | 1 | 2016 | 2796 | 0.080 |
Why?
| | Protein Binding | 1 | 2012 | 1889 | 0.070 |
Why?
| | Alleles | 2 | 2020 | 789 | 0.060 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2023 | 71 | 0.050 |
Why?
| | Gene Expression | 1 | 2008 | 1421 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1214 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2022 | 2762 | 0.050 |
Why?
| | Delphi Technique | 1 | 2022 | 160 | 0.050 |
Why?
| | Aged | 1 | 2018 | 19061 | 0.040 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 452 | 0.040 |
Why?
| | Photic Stimulation | 1 | 2019 | 203 | 0.040 |
Why?
| | Animals | 2 | 2016 | 31694 | 0.040 |
Why?
| | Reaction Time | 1 | 2018 | 376 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 696 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 175 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2018 | 225 | 0.030 |
Why?
| | Oxygen | 2 | 2009 | 854 | 0.030 |
Why?
| | Valproic Acid | 1 | 2014 | 43 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 473 | 0.030 |
Why?
| | Taurine | 1 | 2014 | 41 | 0.030 |
Why?
| | Pregnancy | 1 | 2024 | 5517 | 0.030 |
Why?
| | Child | 2 | 2024 | 18404 | 0.030 |
Why?
| | Age Factors | 1 | 2018 | 2894 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 372 | 0.020 |
Why?
| | Cannabinoids | 1 | 2009 | 115 | 0.020 |
Why?
| | Dronabinol | 1 | 2008 | 118 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4405 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 682 | 0.020 |
Why?
| | Genomics | 1 | 2008 | 635 | 0.010 |
Why?
|
|
Schacht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|